ReviewCancers2021
Additional Value of PET Radiomic Features for the Initial Staging of Prostate Cancer: A Systematic Review from the Literature.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current insights on PSMA PET/CT in intermediate-risk prostate cancer: a literature review.Annals of nuclear medicine · 2025Pooled it
- Impact of partial volume correction on radiomics reproducibility in theranostic SPECT/CT imaging.Medical physics · 2026Article
- Using radiomics model for predicting extraprostatic extension with PSMA PET/CT studies: a comparative study with the Mehralivand grading system.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- The Role of Radiomics and Artificial Intelligence Applied to Staging PSMA PET in Assessing Prostate Cancer Aggressiveness.Journal of clinical medicine · 2025Review
- Can PSMA PET detect intratumour heterogeneity in histological PSMA expression of primary prostate cancer? Analysis of [European journal of nuclear medicine and molecular imaging · 2025Article
- Artificial intelligence algorithm for preoperative prediction of FIGO stage in ovarian cancer based on clinical features integrated 18F-FDG PET/CT metabolic and radiomics features.Journal of cancer research and clinical oncology · 2025Article
- Multi-task Bayesian model combining FDG-PET/CT imaging and clinical data for interpretable high-grade prostate cancer prognosis.Scientific reports · 2024Article
- PET radiomics in lung cancer: advances and translational challenges.EJNMMI physics · 2024Review
- A dynamic online nomogram predicting prostate cancer short-term prognosis based onAbdominal radiology (New York) · 2024Article
- Clinical value of a radiomics model based on machine learning for the prediction of prostate cancer.The Journal of international medical research · 2024Article
- ML Models Built Using Clinical Parameters and Radiomic Features Extracted fromDiagnostics (Basel, Switzerland) · 2024Article
- Robustness of magnetic resonance imaging and positron emission tomography radiomic features in prostate cancer: Impact on recurrence prediction after radiation therapy.Physics and imaging in radiation oncology · 2024Article
- Role of radiomic analysis of [European radiology · 2023Article
- Review
- PET/CT in Prostate Cancer.Cancers · 2023Article
- Article
- The role of [European journal of nuclear medicine and molecular imaging · 2023Article
- Detecting localised prostate cancer using radiomic features in PSMA PET and multiparametric MRI for biologically targeted radiation therapy.EJNMMI research · 2023Article
- Article
- Radiomics in Abdominopelvic Solid-Organ Oncologic Imaging: Current Status.AJR. American journal of roentgenology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed a systematic review of the literature to provide an overview of the application of PET radiomics for the prediction of the initial staging of prostate cancer (PCa), and to discuss the additional value of radiomic features over clinical data. The most relevant databases and web sources were interrogated by using the query "prostate AND radiomic* AND PET". English-language original articles published before July 2021 were considered. A total of 28 studies were screened for eligibility and 6 of them met the inclusion criteria and were, therefore, included for further analysis. All studies were based on human patients. The average number of patients included in the studies was 72 (range 52-101), and the average number of high-order features calculated per study was 167 (range 50-480). The radiotracers used were [68Ga]Ga-PSMA-11 (in four out of six studies), [18F]DCFPyL (one out of six studies), and [11C]Choline (one out of six studies). Considering the imaging modality, three out of six studies used a PET/CT scanner and the other half a PET/MRI tomograph. Heterogeneous results were reported regarding radiomic methods (e.g., segmentation modality) and considered features. The studies reported several predictive markers including first-, second-, and high-order features, such as "kurtosis", "grey-level uniformity", and "HLL wavelet mean", respectively, as well as PET-based metabolic parameters. The strengths and weaknesses of PET radiomics in this setting of disease will be largely discussed and a critical analysis of the available data will be reported. In our review, radiomic analysis proved to add useful information for lesion detection and the prediction of tumor grading of prostatic lesions, even when they were missed at visual qualitative assessment due to their small size; furthermore, PET radiomics could play a synergistic role with the mpMRI radiomic features in lesion evaluation. The most common limitations of the studies were the small sample size, retrospective design, lack of validation on external datasets, and unavailability of univocal cut-off values for the selected radiomic features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.